发明名称 Crystalline form of an inhibitor of MDM2/4 and p53 interaction
摘要 A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively.
申请公布号 US9073898(B2) 申请公布日期 2015.07.07
申请号 US201113988227 申请日期 2011.11.17
申请人 Novartis AG 发明人 Berghausen Joerg;Ren Haixia
分类号 A61K31/496;C07D401/12 主分类号 A61K31/496
代理机构 代理人 Han Michelle
主权项 1. A method of treating leukemia in a patient comprising the step of: administering a therapeutically effective amount of a crystalline form of (S)-1-(4-Chloro-phenyl)-7isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one as a bisulphate salt to the patient in need thereof.
地址 Basel CH